Piper Sandler analyst David Amsellem raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $219 from $147 and keeps an Overweight rating on the shares. With Jazz recently announcing positive top-line results from the pivotal HERIZON-GEA-01 study evaluating novel bispecific HER2-directed antibody zanidatamab in HER2+ first-line advanced/metastatic gastroesophageal adenocarcinoma, the firm is updating its model to reflect significantly less risk-adjustment associated with its sales estimates for the product.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Exact Sciences, Regeneron, Marvell, JFrog, Jazz: Trending by Analysts
- Booking, Carvana upgraded: Wall Street’s top analyst calls
- Jazz Pharmaceuticals downgraded to Neutral from Buy at UBS
- Hold Rating for Jazz Pharmaceuticals Amid Balanced Risk-Reward and Competitive Challenges
- Zymeworks price target raised to $40 from $30 at Stifel